Anatomical and Functional Outcomes after Endoresection and Adjuvant Ruthenium Brachytherapy for Uveal Melanoma: A Single-Center Experience.
Cinzia MazziniGiulio ViciniLaura Di LeoDaniela MassiStanislao RizzoFabrizio GiansantiPublished in: Life (Basel, Switzerland) (2023)
Endoresection and adjuvant Ru-106 brachytherapy is a valuable conservative option for selected UM patients and can be used both as a primary treatment and as a salvage therapy. It can control melanoma and avoid enucleation, reduce radiation-related complications, and provide tumor tissue for chromosomal analysis and prognostic testing.
Keyphrases
- high dose
- early stage
- end stage renal disease
- radiation therapy
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- stem cells
- prognostic factors
- skin cancer
- squamous cell carcinoma
- risk factors
- locally advanced
- gene expression
- copy number
- mesenchymal stem cells
- dna methylation
- patient reported outcomes
- cell therapy
- smoking cessation